Calcium Citrate
ApprovedSmall molecule
Calcium Citrate is one of 53 small molecule programs targeting Rheumatoid Arthritis. It is currently in Approved.
2
Indications
2
Total Trials
0
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
791 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1Calcium Citrate
CCampus Bio-Medico University
Approved
Orencia
Bristol-Myers SquibbPreclinical
Actemra
RochePreclinical
Enbrel
IImmunex
Preclinical
Remicade
OOrganon and Co
Preclinical
Arcoxia
NovartisPreclinical
Actos
TakedaPreclinical
Kineret
SSwedish Orphan Biovitrum
Preclinical
Rituxan
PfizerPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypoparathyroidism1 trial
Efficacy of Calcium Citrate Versus Calcium Carbonate for the Management of Chronic Hypoparathyroidism
Completed·—·Phase 4·NCT03425747·26 enrolled
Rheumatoid Arthritis1 trial
Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial
Completed·—·Phase 4·NCT01400516·26 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Calcium Citrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- CCampus Bio-Medico University